Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Business Wire
Supported by distinguished Scientific Advisory Board of industry and academic leaders in translational science and drug development PARIS--(BUSINESS WIRE)--Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Yvonne McGrath, Ph.D. as Chief Scientific Officer. With over 25 years of experience in biopharma drug development and life sciences, Dr. McGrath will help optimize Enodia’s proprietary platform, which is designed to discover and develop small-molecule therapies that enable the selective degradation of proteins upstream, effectively destroying disease-driving proteins at the point of synthesis.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415535072/en/Yvonne McGrath, PhD“Yvonne joins Enodia to help translate our scientific vision into meaningful clinical progress,” said Yves Ribeill, Chief Executive Off
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore (IMCR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Immunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- A Look At Immunocore (IMCR) Valuation After Jefferies Downgrade And Kimmtrak Growth Concerns [Yahoo! Finance]Yahoo! Finance
- Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive OfficerGlobeNewswire
IMCR
Earnings
- 2/25/26 - Miss
IMCR
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEF
- 4/8/26 - Form 144
- IMCR's page on the SEC website